Top

Published in:

01-07-2022 | Pityriasis Lichenoides Chronica | Original Paper

The role of NLRP1 and NLRP3 inflammasomes in the etiopathogeneses of pityriasis lichenoides chronica and mycosis fungoides: an immunohistochemical study

Authors: Ecem Bostan, Ozay Gokoz, Nilgun Atakan

Published in: Archives of Dermatological Research | Issue 2/2023

Abstract

Mycosis fungoides (MF) is the most common subtype of primary cutaneous T cell lymphomas, whereas pityriasis lichenoides chronica (PLC) is a chronic inflammatory skin disorder. The inflammasome is a part of the natural immune system which has a multimeric structure consisting of the receptor, adaptor and effector protein that show specificity for various ligands or activators. After the activation of the inflammasome complex, caspase 1 becomes activated which subsequently triggers interleukin-18 (IL-18) and interleukin-1β (IL-1β) production. In our study we aimed to examine the roles of nucleotide-binding oligomerization domain-like receptor containing pyrin domain 1 (NLRP1) and nucleotide-binding oligomerization domain-like receptor containing pyrin domain (NLRP3) inflammasomes in the etiopathogeneses of PLC and MF. NLRP1, NLRP3, caspase 1, IL-18 and IL-1β levels were examined and compared immunohistochemically in the skin biopsies belonging to 16 control patients; 16 PLC cases, 12 cases with stage 1 MF and 12 cases with other stages of MF (stage 2–4). In the paired comparisons of NLRP1, stage 2–4 MF group and PLC group were shown to have increased levels of NLRP1 expression compared to the control group. IL-1β was also expressed at statistically significantly higher levels in each of the stage 1 MF, stage 2–4 MF and PLC groups compared to the control group. In the paired comparisons of caspase 1 and IL-18, it was found that stage 1 MF, stage 2–4 MF and PLC groups had increased levels of expression compared to the control group. Our findings suggest that the NLRP1 inflammasome pathway might play a role in the etiopathogenesis and progression of PLC and MF.

Available only for authorised users

Cerroni L (2018) Mycosis fungoides-clinical and histopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg 37:2–10. https://doi.org/10.12788/j.sder.2018.002CrossRefPubMed

Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, Zackheim H, Duvic M, Estrach T, Lamberg S, Wood G, Dummer R, Ranki A, Burg G, Heald P, Pittelkow M, Bernengo MG, Sterry W, Laroche L, Trautinger F, Whittaker S, ISCL, EORTC (2007) Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110:1713–1722. https://doi.org/10.1182/blood-2007-03-055749CrossRefPubMed

Olsen EA (2015) Evaluation, diagnosis, and staging of cutaneous lymphoma. Dermatol Clin 33:643–654. https://doi.org/10.1016/j.det.2015.06.001CrossRefPubMed

Rosen ST, Radvany R, Roenigk H Jr, Terasaki PI, Bunn PA Jr (1985) Human leukocyte antigens in cutaneous T cell lymphoma. J Am Acad Dermatol 12:531–534. https://doi.org/10.1016/s0190-9622(85)70075-8CrossRefPubMed

Dreno B, Celerier P, Fleischmann M, Bureau B, Litoux P (1994) Presence of Epstein-Barr virus in cutaneous lesions of mycosis fungoides and Sézary syndrome. Acta Derm Venereol 74:355–357. https://doi.org/10.2340/0001555574355357CrossRefPubMed

Tuyp E, Burgoyne A, Aitchison T, MacKie R (1987) A case-control study of possible causative factors in mycosis fungoides. Arch Dermatol 23:196–200CrossRef

Ravat FE, Spittle MF, Russell-Jones R (2006) Primary cutaneous T cell lymphoma occurring after organ transplantation. J Am Acad Dermatol 54:668–675. https://doi.org/10.1016/j.jaad.2005.10.015CrossRefPubMed

Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, Ubriani R, Vittorio CC, Junkins-Hopkins JM, Wysocka M, Rook AH (2005) Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin 115:798–812. https://doi.org/10.1172/JCI24826CrossRef

Bowers S, Warshaw EM (2006) Pityriasis lichenoides and its subtypes. J Am Acad Dermatol 55:557–572. https://doi.org/10.1016/j.jaad.2005.07.058CrossRefPubMed

10.

Zaaroura H, Sahar D, Bick T, Bergman R (2018) Relationship between pityriasis lichenoides and mycosis fungoides: a clinicopathological, immunohistochemical, and molecular study. Am J Dermatopathol 40:409–415. https://doi.org/10.1097/DAD.0000000000001057CrossRefPubMed

11.

Kanneganti TD (2015) The inflammasome: firing up innate immunity. Immunol Rev 265:1–5. https://doi.org/10.1111/imr.12297CrossRefPubMedPubMedCentral

12.

Chan AH, Schroder K (2020) Inflammasome signaling and regulation of interleukin-1 family cytokines. J Exp Med 217:e20190314. https://doi.org/10.1084/jem.20190314CrossRefPubMed

13.

Sharma D, Kanneganti TD (2016) The cell biology of inflammasomes: mechanisms of inflammasome activation and regulation. J Cell Biol 213:617–629. https://doi.org/10.1083/jcb.201602089CrossRefPubMedPubMedCentral

14.

Zhong FL, Mamaï O, Sborgi L, Boussofara L, Hopkins R, Robinson K, Szeverényi I, Takeichi T, Balaji R, Lau A, Tye H, Roy K, Bonnard C, Ahl PJ, Jones LA, Baker PJ, Lacina L, Otsuka A, Fournie PR, Malecaze F, Lane EB, Akiyama M, Kabashima K, Connolly JE, Masters SL, Soler VJ, Omar SS, McGrath JA, Nedelcu R, Gribaa M, Denguezli M, Saad A, Hiller S, Reversade B (2016) Germline NLRP1 mutations cause skin inflammatory and cancer susceptibility syndromes via inflammasome activation. Cell 167:187-202.e17. https://doi.org/10.1016/j.cell.2016.09.001CrossRefPubMed

15.

Eyraud A, Milpied B, Thiolat D, Darrigade AS, Boniface K, Taïeb A, Seneschal J (2018) Inflammasome activation characterizes lesional skin of folliculitis decalvans. Acta Derm Venereol 98:570–575. https://doi.org/10.2340/00015555-2924CrossRefPubMed

16.

Silva LM, de Sousa JR, Hirai KE, Dias LB Jr, Furlaneto IP, Carneiro FRO, de Souza Aarão TL, Sotto MN, Quaresma JAS (2018) The inflammasome in leprosy skin lesions: an immunohistochemical evaluation. Infect Drug Resist 11:2231–2240. https://doi.org/10.2147/IDR.S172806CrossRefPubMedPubMedCentral

17.

Awad F, Assrawi E, Louvrier C, Jumeau C, Giurgea I, Amselem S, Karabina SA (2018) Photoaging and skin cancer: Is the inflammasome the missing link? Mech Ageing Dev 172:131–137. https://doi.org/10.1016/j.mad.2018.03.003CrossRefPubMed

18.

Ahmad I, Muneer KM, Chang ME, Nasr HM, Clay JM, Huang CC, Yusuf N (2017) Ultraviolet radiation-induced downregulation of SERCA2 mediates activation of NLRP3 inflammasome in basal cell carcinoma. Photochem Photobiol 93:1025–1033. https://doi.org/10.1111/php.12725CrossRefPubMed

19.

Marie J, Kovacs D, Pain C, Jouary T, Cota C, Vergier B, Picardo M, Taieb A, Ezzedine K, Cario-André M (2014) Inflammasome activation and vitiligo/nonsegmental vitiligo progression. Br J Dermatol 170:816–823. https://doi.org/10.1111/bjd.12691CrossRefPubMed

20.

Rathinam VA, Fitzgerald KA (2016) Inflammasome complexes: emerging mechanisms and effector functions. Cell 165:792–800. https://doi.org/10.1016/j.cell.2016.03.046CrossRefPubMedPubMedCentral

21.

Stutz A, Golenbock DT, Latz E (2009) Inflammasomes: too big to miss. J Clin Invest 119:3502–3511. https://doi.org/10.1172/JCI40599CrossRefPubMedPubMedCentral

22.

Yoshikawa FS, Ferreira LG, de Almeida SR (2015) IL-1 signaling inhibits Trichophyton rubrum conidia development and modulates the IL-17 response in vivo. Virulence 6:449–457. https://doi.org/10.1080/21505594.2015.1020274CrossRefPubMedPubMedCentral

23.

Mao L, Zhang L, Li H, Chen W, Wang H, Wu S, Guo C, Lu A, Yang G, An L, Abliz P, Meng G (2014) Pathogenic fungus Microsporum canis activates the NLRP3 inflammasome. Infect Immun 82:882–892. https://doi.org/10.1128/IAI.01097-13CrossRefPubMedPubMedCentral

24.

Liang N, Yang YP, Li W, Wu YY, Zhang ZW, Luo Y, Fan YM (2018) Overexpression of NLRP3, NLRC4 and AIM2 inflammasomes and their priming-associated molecules (TLR2, TLR4, Dectin-1, Dectin-2 and NFκB) in Malassezia folliculitis. Mycoses 61:111–118. https://doi.org/10.1111/myc.12711CrossRefPubMed

25.

Kaneko N, Kurata M, Yamamoto T, Morikawa S, Masumoto J (2019) The role of interleukin-1 in general pathology. Inflamm Regen 39:12. https://doi.org/10.1186/s41232-019-0101-5CrossRefPubMedPubMedCentral

26.

Savvateeva MV, Savina MI, Markusheva LI, Samsonov VA (2002) Relative content of cytokines in different tissues in mycosis fungoides. Bull Exp Biol Med 134:175–176. https://doi.org/10.1023/a:1021148601424CrossRefPubMed

27.

Yamanaka K, Clark R, Dowgiert R, Hurwitz D, Shibata M, Rich BE, Hirahara K, Jones DA, Eapen S, Mizutani H, Kupper TS (2006) Expression of interleukin-18 and caspase-1 in cutaneous T-cell lymphoma. Clin Cancer Res 12:376–382. https://doi.org/10.1158/1078-0432.CCR-05-1777CrossRefPubMed

28.

Pileri A, Neri I, Raone B, Ciabatti S, Bellini F, Patrizi A (2012) Mycosis fungoides following pityriasis lichenoides: an exceptional event or a potential evolution. Pediatr Blood Cancer 58:306. https://doi.org/10.1002/pbc.23260CrossRefPubMed

Title: The role of NLRP1 and NLRP3 inflammasomes in the etiopathogeneses of pityriasis lichenoides chronica and mycosis fungoides: an immunohistochemical study
Authors: Ecem Bostan
Ozay Gokoz
Nilgun Atakan
Publication date: 01-07-2022
Publisher: Springer Berlin Heidelberg
Keywords: Pityriasis Lichenoides Chronica
Lichenoid Pityriasis
Mycosis Fungoides
Published in: Archives of Dermatological Research / Issue 2/2023
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-022-02363-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The role of NLRP1 and NLRP3 inflammasomes in the etiopathogeneses of pityriasis lichenoides chronica and mycosis fungoides: an immunohistochemical study

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2023

Lower lip basal cell and squamous cell carcinomas: a reappraisal of the similarities and differences in clinical presentation and management

Apremilast and narrowband ultraviolet B combination therapy suppresses Th17 axis and promotes melanogenesis in vitiligo skin: a randomized, split-body, pilot study in skin types IV–VI

VEXAS syndrome in dermatology

Levamisole-induced and COVID-19-induced retiform purpura: two overlapping, emerging clinical syndromes

Oculocutaneous albinism: epidemiology, genetics, skin manifestation, and psychosocial issues

A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata